Core Insights - Artisan Partners' "Artisan Value Fund" reported a positive performance in Q3 2025, with returns of 0.83%, 0.91%, and 0.90% for its Investor Class, Advisor Class, and Institutional Class, respectively, against a 5.33% return for the Russell 1000 Value Index [1] Company Analysis - Elevance Health, Inc. (NYSE:ELV) is highlighted as a key stock in the Artisan Value Fund's portfolio, with a one-month return of 5.28% and a 52-week loss of 5.56%, closing at $348.38 per share with a market capitalization of $77.42 billion on December 29, 2025 [2] - The fund made a strategic decision to purchase Elevance Health, swapping it for Cigna, as both companies operate in the health insurance sector but have different business mixes. Elevance is noted for its diverse offerings in commercial, Medicare Advantage, and Medicaid, while Cigna has a larger pharmacy benefits management (PBM) business [3] - The investment case for Elevance is based on the expectation that its currently depressed earnings will recover as pricing adjusts to rising costs, with shares trading under 10X expected earnings per share compared to a 10-year average of 16X [3]

Core Insights - Elevance Health, Inc. is a prominent healthcare company with a market capitalization of $71.7 billion, serving approximately 46.8 million members through various health plans and services [1] Financial Performance - The company is set to announce its fiscal Q3 earnings for 2025 on October 21st, with analysts projecting a profit of $5.01 per share, representing a 40.1% decline from $8.37 per share in the same quarter last year [2] - For the current year, analysts expect Elevance Health to report an EPS of $29.89, down 9.5% from $33.04 in fiscal 2024, but anticipate a rebound in FY2026 with a projected EPS of $30.96, reflecting a 3.6% year-over-year increase [3] Stock Performance - Shares of Elevance Health have decreased by 38.8% over the past 52 weeks, significantly underperforming compared to the S&P 500 Index, which has increased by 15.6%, and the Health Care Select Sector SPDR Fund, which has seen an 11.5% loss during the same period [4] Market Sentiment - Wall Street analysts maintain a "Moderate Buy" rating for Elevance Health, with 13 out of 21 analysts recommending "Strong Buy," one suggesting "Moderate Buy," six indicating "Hold," and one advising "Strong Sell." The mean price target for the stock is $359.06, suggesting a potential upside of 12.7% from current levels [6] Regulatory Environment - On September 25, shares of Elevance Health fell by 3% following the U.S. Commerce Department's initiation of a national security investigation into medical equipment imports, which could lead to new tariffs and create uncertainty within the healthcare sector [5]